Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibition of RAS, RAF and MEK

被引：0
|
作者：
Coma, Silvia [1 ]
Chowdhury, Sanjib [1 ]
Dilly, Julien [2 ]
Musteanu, Monica [3 ]
Barbacid, Mariano [3 ]
Aguirre, Andrew J. [2 ]
Pachter, Jonathan A. [1 ]
机构：
[1] Verastem Oncol, Needham, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Ctr Nacl Invest Oncol, Madrid, Spain
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
402
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK
    Coma, Silvia
    Musteanu, Monica
    Caffarra, Cristina
    Mira, Alessia
    Patrucco, Enrico
    Dilly, Julien
    Aguirre, Andrew J.
    Barbacid, Mariano
    Ambrogio, Chiara
    Pachter, Jonathan A.
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [2] Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pathway inhibition strategy.
    Coma, Silvia
    Chowdhury, Sanjib
    Pachter, Jonathan A.
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants
    Coma, S.
    Chowdhury, S.
    Musteanu, M.
    Stewart, A.
    Pickard, L.
    Krebs, M.
    Minchom, A.
    Banerji, U.
    Barbacid, M.
    Pachter, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1124 - S1124
  • [4] Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumors.
    Coma, Silvia
    Paradis, Justine S.
    Gutkind, J. Silvio
    Pachter, Jonathan A.
    CANCER RESEARCH, 2021, 81 (13)
  • [5] Trial in progress: Combination of the dual RAF/MEK inhibitor VS-6766 with the mTOR inhibitor everolimus with expansion in patients with KRAS mutant NSCLC
    Manickavasagar, Thubeena
    Stavraka, Chara
    Anam, Kaiser
    Coma, Silvia
    Chowdhury, Sanjib
    Pachter, Jonathan A.
    Parker, Tom
    Parmar, Mona
    Finneran, Laura
    Hall, Emma
    Spicer, James
    Minchom, Anna
    Banerji, Udai
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [6] Dual RAF/MEK inhibitor VS-6766 for treatment of solid tumors with diverse MAPK pathway alterations
    Coma, Silvia
    Chowdhury, Sanjib
    Musteanu, Monica
    Barbacid, Mariano
    Pachter, Jonathan A.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [7] A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC.
    Krebs, Matthew G.
    Shinde, Rajiv
    Rahman, Rozana Abdul
    Grochot, Rafael
    Little, Martin
    King, Jenny
    Kitchin, Joseph
    Parmar, Mona
    Turner, Alison
    Mahmud, Muneeb
    Yap, Christina
    Tunariu, Nina
    Lopez, Juanita
    De Bono, Johann S.
    Banerji, Udai
    Minchom, Anna
    CANCER RESEARCH, 2021, 81 (13)
  • [8] A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
    Govindan, Ramaswamy
    Awad, Mark M.
    Gadgeel, Shirish M.
    Pachter, Jonathan A.
    Patrick, Gloria
    Denis, Louis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer
    McNamara, Blair
    Demirkiran, Cem
    Bellone, Stefania
    Mutlu, Levent
    Zipponi, Margherita
    Verzosa, Miguel S.
    Harold, Justin
    Hartwich, Tobias M.
    Altwerger, Gary
    Ratner, Elena
    Huang, Gloria
    Clark, Mitchell
    Andikyan, Vaagn
    Azodi, Masoud
    Schwartz, Peter E.
    Dottino, Peter
    Santin, Alessandro D.
    CANCER RESEARCH, 2023, 83 (07)
  • [10] Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
    Banerjee, S.
    Grochot, R.
    Shinde, R.
    Lima, J.
    Krebs, M.
    Rahman, R.
    Little, M.
    Tunariu, N.
    Curcean, A.
    Badham, H.
    Mahmud, M.
    Turner, A.
    Parmar, M.
    Yap, C.
    Minchom, A.
    Lopez, J.
    de Bono, J.
    Banerji, U.
    ANNALS OF ONCOLOGY, 2021, 32 : S728 - S728
12345